Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.

@article{Eve2012SingleagentLI,
  title={Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.},
  author={Heather E Eve and Sean D. Carey and Sarah J. Richardson and Carla C. Heise and Vidya Mamidipudi and Tao Shi and John Radford and Rebecca L. Auer and Sheila H Bullard and Simon Rule},
  journal={British journal of haematology},
  year={2012},
  volume={159 2},
  pages={154-63}
}
We present data from a phase II study investigating a novel treatment strategy for relapsed/refractory mantle cell lymphoma (MCL). Twenty-six patients received lenalidomide 25 mg/d (days 1-21 of a 28-d cycle) for up to 6 cycles followed by low-dose maintenance lenalidomide (15 mg) in responding patients. Eight patients achieved complete or partial response to give an overall response rate of 31% with median response duration of 22·2 months [95% confidence interval (CI) 0·0-53·6] and median… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…